Can a drug cocktail revive immunotherapy for breast cancer?

NCT ID NCT05076682

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing several drug combinations (including choline, sodium cromoglicate, efavirenz, and others) alongside immunotherapy to see if they can reverse resistance in triple-negative breast cancer that has progressed after prior immunotherapy. About 80 participants with metastatic or locally advanced disease will be enrolled. The goal is to find a safe and effective way to make tumors respond again to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination of drugs (choline, sodium cromoglicate, efavirenz, SHR-A1811, SHR-A2102, SHR-1316, mecapegfilgrastim, AK131, and others) plus an immune checkpoint inhibitor
What this could lead to: If it works, this could point toward a way to re-sensitize triple-negative breast cancer to immunotherapy, offering a new treatment option for patients who have stopped responding.
What could go wrong: This is an early phase 2 trial with only 80 participants and multiple drug combinations, so it is unclear which combination works best or if any will prove effective. Side effects from the drug cocktail may also be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.